[HTML][HTML] innovative radiopharmaceuticals in oncology and Neurology
J Barbet, N Arlicot, MH Gaugler, M Chérel… - Frontiers in …, 2017 - frontiersin.org
Personalized medicine is presented as the future of patient care. Nuclear Medicine will play
a major role in the selection of patients for targeted therapies and in early therapy …
a major role in the selection of patients for targeted therapies and in early therapy …
Innovative Radiopharmaceuticals in Oncology and Neurology
M Cherel, J Barbet, F Kraeber-Bodere, D Guilloteau - 2017 - katalog.ub.uni-heidelberg.de
The aim of this Research Topic was to assemble a series of articles describing basic,
preclinical and clinical research studies on radiopharmaceuticals and nuclear medicine. The …
preclinical and clinical research studies on radiopharmaceuticals and nuclear medicine. The …
[HTML][HTML] Innovative Radiopharmaceuticals in Oncology and Neurology
J Barbet, N Arlicot, MH Gaugler, M Chérel… - Frontiers in …, 2016 - ncbi.nlm.nih.gov
Personalized medicine is presented as the future of patient care. Nuclear Medicine will play
a major role in the selection of patients for targeted therapies and in early therapy …
a major role in the selection of patients for targeted therapies and in early therapy …
[PDF][PDF] Innovative Radiopharmaceuticals in Oncology and Neurology
D Guilloteau, F Kraeber-Bodéré - Frontiers, 2017 - academia.edu
Personalized medicine is presented as the future of patient care. Nuclear Medicine will play
a major role in the selection of patients for targeted therapies and in early therapy …
a major role in the selection of patients for targeted therapies and in early therapy …
innovative radiopharmaceuticals in oncology and Neurology
J Barbet, N Arlicot, MH Gaugler, M Chérel… - Frontiers in …, 2017 - hal.science
Editorial on the Research Topic Innovative Radiopharmaceuticals in Oncology and
Neurology Personalized medicine is presented as the future of patient care. Nuclear …
Neurology Personalized medicine is presented as the future of patient care. Nuclear …
Innovative Radiopharmaceuticals in Oncology and Neurology
J Barbet, N Arlicot, MH Gaugler… - Frontiers in …, 2017 - pubmed.ncbi.nlm.nih.gov
Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology Editorial: Innovative
Radiopharmaceuticals in Oncology and Neurology Front Med (Lausanne). 2017 Jan 11:3:74 …
Radiopharmaceuticals in Oncology and Neurology Front Med (Lausanne). 2017 Jan 11:3:74 …
Innovative Radiopharmaceuticals in Oncology and Neurology.
J Barbet, N Arlicot, MH Gaugler, M Chérel… - Frontiers in …, 2017 - europepmc.org
Personalized medicine is presented as the future of patient care. Nuclear Medicine will play
a major role in the selection of patients for targeted therapies and in early therapy …
a major role in the selection of patients for targeted therapies and in early therapy …
[图书][B] Innovative Radiopharmaceuticals in Oncology and Neurology
F Kraeber-Bodéré, J Barbet, M Chérel, D Guilloteau - 2017 - books.google.com
The aim of this Research Topic was to assemble a series of articles describing basic,
preclinical and clinical research studies on radiopharmaceuticals and nuclear medicine. The …
preclinical and clinical research studies on radiopharmaceuticals and nuclear medicine. The …
[PDF][PDF] innovative radiopharmaceuticals in oncology and Neurology
J Barbet, N Arlicot, MH Gaugler, M Chérel, D Guilloteau… - Frontiers, 2017 - core.ac.uk
Personalized medicine is presented as the future of patient care. Nuclear Medicine will play
a major role in the selection of patients for targeted therapies and in early therapy …
a major role in the selection of patients for targeted therapies and in early therapy …
[PDF][PDF] innovative radiopharmaceuticals in oncology and Neurology
J Barbet, N Arlicot, MH Gaugler, M Chérel, D Guilloteau… - Frontiers, 2017 - researchgate.net
Personalized medicine is presented as the future of patient care. Nuclear Medicine will play
a major role in the selection of patients for targeted therapies and in early therapy …
a major role in the selection of patients for targeted therapies and in early therapy …